Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178345 | 0.84 | PPARG (0.40) | DUTPPARGPPARAKMT2ALTA4H | |
| SCHEMBL17887376 | 0.81 | IDO1 (0.49) | DUTKMT2A | |
| SCHEMBL3403690 | 0.81 | DUT (0.43) | DUT | |
| SCHEMBL662362 | 0.81 | PPARG (0.41) | DUTPPARGPPARAKMT2ALTA4H | |
| SCHEMBL1628199 | 0.80 | LOXL2 (0.45) | DUTKMT2A | |
| SCHEMBL662532 | 0.79 | DUT (0.40) | DUTPPARGPPARAKMT2A | |
| SCHEMBL29132544 | 0.78 | L3MBTL1 (0.41) | DUTKMT2A | |
| SCHEMBL1627173 | 0.77 | DUT (0.40) | DUTPPARGPPARAKMT2ASLC6A2 | |
| SCHEMBL12002629 | 0.77 | IDO1 (0.40) | PPARGPPARAKMT2A | |
| SCHEMBL2560206 | 0.77 | L3MBTL1 (0.47) | DUTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242063-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-3323810-B1 | AUTOMATED REACTION SYSTEM, CASSETTE AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3323810-B1 | AUTOMATED REACTION SYSTEM, CASSETTE AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-109200296-B | Method and apparatus for synthesizing imaging agents and intermediates thereof | 兰休斯医疗成像公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| CN-113058046-A | Method and apparatus for synthesizing imaging agents and intermediates thereof | 兰休斯医疗成像公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210187131-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210187131-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1713512-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1713512-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Pharma Company (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005079391-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | DUT 572/4885PTPN2 4339/4885PTPN1 3372/4885 |
| US-20210187131-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | TNNI3, FABP3, MPI | DUT 34/4885PTPN2 3379/4885PTPN1 2674/4885 |
| US-20250242063-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | TNNI3, FABP3, MPI | DUT 34/4885PTPN2 3379/4885PTPN1 2674/4885 |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | FABP7, MKI67, SLC5A7 | DUT 1089/4885PTPN2 4124/4885PTPN1 3729/4885 |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | DUT 572/4885PTPN2 4339/4885PTPN1 3372/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | DUT 572/4885PTPN2 4339/4885PTPN1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.